KAPLAN GILLA
Known title: DirectorCIK: 0001247024
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop. Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.
Transaction History
| AVTX | ▲ Buy | Option Exercise | 3,166 | — | 3/28/2026 | View on chart |
| TYRA | ▼ Sell | Other | 53,172 | $2.0M | 3/26/2026 | View on chart |
| TYRA | ▲ Buy | Option Exercise | 53,172 | $120K | 3/26/2026 | View on chart |
| TYRA | ▲ Buy | Option Exercise | 14,295 | $32K | 3/25/2026 | View on chart |
| TYRA | ▼ Sell | Open Market | 14,295 | $529K | 3/25/2026 | View on chart |
| TYRA | ▼ Sell | Open Market | 9,568 | $94K | 6/18/2025 | View on chart |
| TYRA | ▼ Sell | Open Market | 10 | $104 | 6/17/2025 | View on chart |
| TYRA | ▼ Sell | Open Market | 6,814 | $71K | 6/16/2025 | View on chart |
| TYRA | ▼ Sell | Open Market | 15,000 | $155K | 6/13/2025 | View on chart |
| TYRA | ▼ Sell | Open Market | 30,000 | $309K | 6/12/2025 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 3,167 | — | 3/28/2025 | View on chart |
| TYRA | ▲ Buy | Option Exercise | 61,392 | $37K | 6/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program
Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program. Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.